Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Percheron Therapeutics ( (AU:PER) ) has issued an update.
Percheron Therapeutics Limited announced its presentation for the Annual General Meeting, highlighting its progress and plans for its lead program, HMBD-002, which targets advanced cancer. The company aims to commence further clinical trials in 2026, signaling a significant step in its development strategy and potential impact on the oncology and rare disease markets.
The most recent analyst rating on (AU:PER) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Percheron Therapeutics Limited is a publicly listed biotechnology company focused on developing and commercializing novel therapies for oncology and rare diseases. Its lead program, HMBD-002, is a monoclonal antibody targeting the immune checkpoint regulator, VISTA, which has completed a phase I clinical trial showing it to be generally safe and well tolerated.
Average Trading Volume: 2,975,046
Technical Sentiment Signal: Sell
Current Market Cap: A$9.79M
For detailed information about PER stock, go to TipRanks’ Stock Analysis page.